 Investment bank B Riley has restated its buy advice and US8 price target for shares in Tiziana Life Sciences PLC LON:TILS NASDAQ:TLSA after a flurry of positive news. It said safety data on key drug Foralumab, signs of its efficacy in COVID-19 patients and its clearance for its use in a patient with MS provided incremental validation of the monoclonal antibody mAb treatment. 